T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy

[1] Ro JY(1987)Muscularis mucosa of urinary bladder. Importance for staging and treatment Am J Surg Pathol 11 668-673

[2] Ayala AG(2009)Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy Eur Urol 56 430-442

[3] el-Naggar A(2004)Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172 70-75

[4] van Rhijn BWB(2006)Predicting recurrence, progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from 7 EORTC trials Eur Urol 49 466-477

[5] Burger M(2007)Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer J Urol 177 1283-1286

[6] Lotan Y(2002)Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 1964-1970

[7] Thalmann GN(2004)Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials BJU Int 93 485-490

[8] Markwalder R(2004)Bladder carcinoma in situ in 2003: state of the art Eur Urol 45 142-146

[9] Studer UE(1982)Toxicity and response criteria of the eastern cooperative oncology group Am J Clin Oncol 5 649-655

[10] Sylvester RJ(2009)Oncological followup after radical cystectomy for bladder cancer-is there any benefit? J Urol 181 1587-1593

[1] Ro JY(1987)Muscularis mucosa of urinary bladder. Importance for staging and treatment Am J Surg Pathol 11 668-673

[2] Ayala AG(2009)Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy Eur Urol 56 430-442

[3] el-Naggar A(2004)Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172 70-75

[4] van Rhijn BWB(2006)Predicting recurrence, progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from 7 EORTC trials Eur Urol 49 466-477

[5] Burger M(2007)Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer J Urol 177 1283-1286

[6] Lotan Y(2002)Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 1964-1970

[7] Thalmann GN(2004)Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials BJU Int 93 485-490

[8] Markwalder R(2004)Bladder carcinoma in situ in 2003: state of the art Eur Urol 45 142-146

[9] Studer UE(1982)Toxicity and response criteria of the eastern cooperative oncology group Am J Clin Oncol 5 649-655

[10] Sylvester RJ(2009)Oncological followup after radical cystectomy for bladder cancer-is there any benefit? J Urol 181 1587-1593